Abbonarsi

Selenium status and survival from colorectal cancer in the European prospective investigation of cancer and nutrition - 05/07/18

Doi : 10.1016/j.respe.2018.05.142 
D. Hughes a, V. Fedirko b, S. Umesh b, L. Schomburg c, C. Méplan d, S. Hybsier c, E. Riboli e, M. Jenab f,

on behalf of EPIC group

a Cancer Biology and Therapeutics Group, Conway Institute, University College Dublin, Dublin, Ireland 
b Rollins School of Public Health, Emory University, Atlanta, United States 
c Institute for Experimental Endocrinology, Charité–Medical University, Berlin, Germany 
d Institute of Cell and Molecular Biosciences, Newcastle University, Newcastle, United Kingdom 
e School of Public Health, Imperial College London, London, United Kingdom 
f Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Introduction

Suboptimal levels of selenium (Se) or selenoprotein P (SELENOP), which is an antioxidant protein that also distributes Se from the liver to target tissues, may contribute to risk of colorectal cancer (CRC) development, as we previously showed using serum samples taken pre-diagnostically in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort [1]. However, the relationship between Se and survival outcomes following cancer diagnosis is more uncertain. Here, we examined the association of Se status with mortality from CRC and overall mortality in the same study group.

Methods

Se was measured by total reflection X-ray fluorescence and SELENOP by immunoluminometric sandwich assay. Multivariable-adjusted Cox proportional hazard models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) of the association between Se and SELENOP and CRC death and all-cause mortality.

Results

Higher levels of Se showed non-significant inverse associations with reduction in both CRC and overall mortality: respective multivariable-adjusted HRs for the fifth quintile versus the first quintile (HRQ5 vs. Q1) were 0.76 (95% CI: 0.52–1.11, Ptrend=0.10), and 0.82 (95% CI: 0.56–1.16, Ptrend=0.14). Higher levels of SELENOP were also not associated with a statistically significant reduction in CRC mortality (HRQ5 vs. Q1=0.83, 95% CI: 0.57–1.19, Ptrend=0.33). However, higher SELENOP concentrations were associated with a significant reduction in overall mortality (HRQ5 vs. Q1=0.70, 95% CI: 0.50–0.98, Ptrend=0.05). Similar results were also obtained by tumour site and sex. Possible interactions of potential effect modifiers and sensitivity analyses showed no considerable change in these estimates, although CRC stage data sensitivity analyses were significant for the association between Se and overall mortality (HRQ5 vs. Q1=0.89, 95% CI: 0.80–0.99, Ptrend=0.03).

Conclusions

We found no major association of Se status markers with survival after CRC diagnosis, but an association of SELENOP with overall mortality. Detailed investigation of Se metabolism is needed to further explore relevance for CRC prognosis especially for individuals of suboptimal SELENOP status.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Selenium, Selenium status, Selenoprotein P, Colorectal neoplasm, Prospective cohort


Mappa


© 2018  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 66 - N° S5

P. S290 - luglio 2018 Ritorno al numero
Articolo precedente Articolo precedente
  • Does administration of broad-spectrum antibiotics in febrile neutropenic children trigger the emergence of BMR? A French experience
  • C. Raad, J. Grando, C. Fuhrmann, C. Bruchon, Y. Bertrand, C. Domenech
| Articolo seguente Articolo seguente
  • Assessing the validity of self-reported breast cancer screening coverage in the Belgian Health Interview survey
  • F. Berete, J. Van der Heyden, S. Demarest, J. Tafforeau, H. Van Oyen, O. Bruyère

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.